17 June 2008 - Boehringer Ingelheim GmbH announced an agreement to acquire Actimis Pharmaceuticals, Inc., a privately owned biotech company based in San Diego. The acquisition will occur through a structured buyout in which Boehringer Ingelheim will acquire shares of Actimis depending on the achievement of several successive milestones with Actimis’ leading asthma compound AP768. If AP768, currently in phase I clinical development, is successfully advanced into a phase III, Boehringer Ingelheim will own 100% of Actimis’ shares. 
Upon successful completion of the entire development programme, the total deal will be worth US$ 515 million. Further financial details were not disclosed... Boehringer Ingelheim's Press Release -
